Selected Publications

• Development of a Peptide-Based Tumor-Activated Checkpoint Inhibitor for Cancer Immunotherapy.

Zhen Zhao, John Fetse, Umar-Farouk Mamani, Yuhan Guo, Yuanke Li, Pratikkumar Patel, Yanli Liu, Chien-Yu Lin, Yongren Li, Bahaa Mustafa, Kun Cheng.  Acta Biomaterialia 2025, 193, 484-497

doi.org/10.1016/j.actbio.2024.12.051

• Exploring Multivalency in the Development of Anti-PD-L1 Peptides for Cancer Immunotherapy.

Umar-Farouk Mamani, Mohammed Nurudeen Ibrahim, Yanli Liu, John Fetse, Chien-Yu Lin, Sashi Kandel, Maryam Nakhjiri, Sushil Koirala, Yuhan Guo, Mohammed Alahmari, Kun Cheng. Pharmaceutical Research 2024, 41, 2275–2288

doi.org/10.1007/s11095-024-03803-1

• Personalized Medicine Approach to Proteomics and Metabolomics of Cytochrome P450 Enzymes: A Narrative Review.

John Fetse, Emmanuel Oladayo Olawode, Subrata Deb. European Journal of Drug Metabolism and Pharmacokinetics 2024, 49, 661–676

doi.org/10.1007/s13318-024-00912-5

• Recent advances in the development of therapeutic peptides. 

John Fetse, Sashi Kandel, Umar-Farouk Mamani, Kun Cheng. Trends in Pharmacological Sciences 2023, 44(7):425-441

doi.org/10.1016/j.tips.2023.04.003

• Discovery of Anti‐CD47 Peptides as Innate Immune Checkpoint Inhibitors. Advanced Therapeutics.

Bahaa Mustafa, John Fetse, Sashi Kandel, Chien‐ Yu Lin, Pratik Adhikary, Umar‐Farouk Mamani, Yanli Liu, Mohammed Nurudeen Ibrahim, Mohammed Alahmari, Kun Cheng. Advanced Therapeutics 2023, 6(12):2300114

doi.org/10.1002/adtp.202300114

• Development of Amino Acid-Modified Biodegradable Lipid Nanoparticles for siRNA Delivery. 

Pratikkumar Patel, John Fetse, Chien-Yu Lin, Zhen Zhao, Maryam Nakhjiri, Akshay Jain, and Kun Cheng.  Acta Biomaterialia, 2022, 154:374-384

doi.org/10.1016/j.actbio.2022.09.065 

• Discovery of Cyclic Peptide Inhibitors Targeting PD-L1 for Cancer Immunotherapy.

John Fetse, Zhen Zhao, Hao Liu, Umar-Farouk Mamani, Bahaa Mustafa, Pratik Adhikary, Nurudeen Mohammed Ibrahim, Yanli Liu, Pratikkumar Patel, Maryam    Nakhjiri, Mohammed Alahmari, Guangfu Li, Kun Cheng. ACS Journal of Medicinal Chemistry 2022, 65(18):12002-12013

doi.org/10.1021/acs.jmedchem.2c00539

• Discovery of Small Anti‐ACE2 Peptides to Inhibit SARS‐CoV‐2 Infectivity. Advanced Therapeutics.

Pratik Adhikary, Sashi Kandel, Umar‐Farouk Mamani, Bahaa Mustafa, Siyuan Hao, Jianming Qiu, John Fetse, Yanli Liu, Nurudeen Mohammed Ibrahim, Yongren Li,  Chien‐Yu Lin, Evanthia Omoscharka, Kun Cheng.  Advanced Therapeutics 2021, 4(7):2100087

doi.org/10.1002/adtp.202100087

• Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma.

Yuanke  Li,  Zhen Zhao, Hao Liu, John Fetse, Akshay Jain, Chien-Yu Lin, and Kun Cheng.  ACS applied materials & interfaces  2019,  11(49):45390-45403 

     doi.org/10.1021/acsami.9b15116

• Targeted Delivery of an siRNA-PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride-Induced Liver Fibrosis.

    Akshay Jain, Ashutosh Barve, Zhen Zhao, John Fetse, Hao Liu, Kun Cheng.  Advanced Therapeutics 2019, 2(8):1900046

    doi.org/10.1002/adtp.201900046

• Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.  

Hao Liu, Zhen Zhao, Li Zhang, Yuanke Li, Akshay Jain, Ashutosh Barve, Wei Jin, Yanli Liu, John Fetse, Kun Cheng.  Journal for Immunotherapy of Cancer 2019,  (1):270 doi.org/10.1186/s40425-019-0705-y